0001726822 false --12-31 0001726822 2023-10-24 2023-10-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported): October 24, 2023

 

SOUL BIOTECHNOLOGY CORP.

(Exact Name of Registrant as Specified in its Charter)

 

Nevada   000-56213   82-3155323
(State of
incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

36 Fourth Ave. N, Yorkton Saskatchewan, Canada   S3N 2V7
(Address of principal executive offices)   (Zip Code)

 

(306) 563-4123

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered under Section 12(g) of the Exchange Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   ADOB   N/A

 

Securities registered pursuant to Section 12(b) of the Act: None

 

 

 

 

 

 

Item 5.03 Amendments to Articles of Incorporation or By-Laws; Change in Fiscal Year.

 

On October 24, 2023, Soul Biotechnology Corp. (the “Company”), amended its articles of incorporation, changing its name to Adorbs Inc. The change was made back to the Company’s original name to facilitate potential DTC eligibility.

 

Item 9.01. Financial Statements and Exhibits.

 

Exhibit No.   Description
3.1   Certificate of Amendment, filed October 24, 2023

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

October 27, 2023

 

SOUL BIOTECHNOLOGY CORP.  
     
  /s/ Rachel Martinuik  
By: Rachel Martinuik  
Title: CEO  

 

2

 

Exhibit 3.1

 

 

 

 

 

 

 

v3.23.3
Cover
Oct. 24, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 24, 2023
Current Fiscal Year End Date --12-31
Entity File Number 000-56213
Entity Registrant Name SOUL BIOTECHNOLOGY CORP
Entity Central Index Key 0001726822
Entity Tax Identification Number 82-3155323
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 36 Fourth Ave. N
Entity Address, Address Line Two Yorkton
Entity Address, City or Town Saskatchewan
Entity Address, State or Province SK
Entity Address, Country CA
Entity Address, Postal Zip Code S3N 2V7
City Area Code (306)
Local Phone Number 563-4123
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ADOB
Entity Emerging Growth Company false

Grafico Azioni Adorbs (CE) (USOTC:ADOB)
Storico
Da Nov 2024 a Dic 2024 Clicca qui per i Grafici di Adorbs (CE)
Grafico Azioni Adorbs (CE) (USOTC:ADOB)
Storico
Da Dic 2023 a Dic 2024 Clicca qui per i Grafici di Adorbs (CE)